Faxe	d prescriptions will only be accepted	from a prescribing practitioner.	Patients must bring an original presc	ription to the pharn	rmacy, and cannot fax these referral forms to Senderra.				
SENDERRA		Juvenile	Prescriber:	NPI:	NPI:				
		Idiopathic Arthritis (JIA)	Supervising Physician:			NPI:	NPI:		
		Enrollment Form I - Z	Address:			Tax ID:	Tax ID:		
Specialty Pharmacy		yo.o.a ooo			Fax:				
3712 E. Plano Parkway, Ste. 200		Call:                     855-460-7928         Contact:							
Plano, TX 75074  This prescription form is to be sent & received via fax  Fax: 888-777-5645									
PATIENT INFORMATION									
Name:		□ M □ F □ Trans M □ Trans F □ Other □ DOB:			SS#: 				
Street:		City	<i>y</i> :	State:		ZIP:			
Phone:         Alt. Phone:         □ English □ Spanish □ Other:         Wt.:         Ht.:									
PRESCRIPTION									
□ <sub>New</sub> □	Refill Ship by: _		SHIP TO: Patient's F	lome Docto	or's Office	Other:			
Drug		Directions					Quantity	Refills	
Kevzara <sup>®</sup>	200 mg Pre-filled Syringe	☐ Inject 200 mg SQ every 2 weeks			***WEIGHT REQUIRED***		2		
	, ,	***Intended for weight ≥ 63 kg/138 lbs***  INTRAVENOUS (IV):							
		□ INITIAL: Infuse mg via IV on week 0, 2, and 4					QS: 3 doses		
	250 mg Vial WEIGHT	INITIAL: Infuse mg via IV on week 0, 2, and 4 ***WEIGHT BASED GU (<75 kg: 10 mg					Q5: 3 doses		
Orencia®	REQUIRED:	(75 kg-10			(75 kg-10	(75 kg-100 kg: 750 mg)			
					g: 1000 mg)	QS: 1 dose			
		SUBCUTANEOUS (SQ):							
	Pre-filled Syringe	Inject 50 mg SQ once weekly (10 kg to less than 25 kg)				REQUIRED***	4		
	☐ ClickJect ™	☐ Inject 87.5 mg SQ once weekly (25 kg to less than 50 kg) ☐ Inject 125 mg SQ once weekly (≥50 kg)							
Rinvoq®	15mg Tablet		☐ Take 15 mg PO once daily (≥30 kg)				30		
	Torng Tublot				***WEIGHT R	EQUIRED***	1 bottle		
Rinvoq® LQ 1 mg/mL Solution		Take 4 mg PO twice daily (20 kg to less than 30 kg)					1 bottle 2 bottles		
			☐ Take 6 mg PO twice daily (≥40 kg) ☐ INITIAL: Inject						
Stelara®	☐ 45 mg Vial	☐ INITIAL: Inject mg (0.75 mg/kg xkg) SQ at weeks 0 & 4 ***WEIGHT REQUIRED***  ☐ MAINTENANCE: Inject mg (0.75 mg/kg xkg) SQ every 12					QS: 2 doses	-	
	— 40 mg viai	weeks ***Intended for wei				eight < 60 kg/132 lbs***	QS: 1 dose		
	☐ 45 mg Pre-filled Syringe	INITIAL: Inject 45 mg SQ at weeks 0 & 4			***Intended for weight ≥ 60 kg/132 lbs***		2	-	
	_	MAINTENANCE: Inject 45 mg SQ every 12 weeks  Inject 90 mg SQ at weeks 0 & 4			***Intended for weight > 100 kg/220 lbs		2	-	
	☐ 90 mg Pre-filled Syringe		MAINTENANCE: Inject 90 mg SQ every 12 weeks			with co-existent moderate-to-severe plaque psoriasis***			
	5 mg Tablet	Take 5 mg PO twice of	daily				60		
Xeljanz <sup>®</sup>		Take 3.2 mg PO twice daily (10 kg to less than 20 kg)			***WEIGHT REQUIRED***				
_	1 mg/mL Solution	Take 4 mg PO twice daily (20 kg to less than 40 kg)					240		
☐ Take 5 mg PO twice daily (≥40 kg)  MEDICAL INFORMATION									
MEDICAL INFORMATION  ***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY***									
PREVIOUS THE		ied & Failed (Duration):	Not Tolerated:		Co	ntraindication:			
☐ Methotrexate ☐(		)		-					
☐ Sulfasalazine ☐(		)		-					
☐ Meloxicam ☐( ☐ Enbrel ☐(		)		-					
☐ Enbrel ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐		)	)						
				-					
Date of Diagno	sis: / / pecified Juvenile Idiopathic Arthr	itis of Unspecified Site	Allergies:  M08.09 Unspecified juver	nile rheumatoid a	arthritis, multiple	e sites (pcJIA)			
☐ L40.54 Psoria	atic juvenile arthropathy (JPsA)		Other:						
Active TB is rule Additional Clini	d out: $\square_{Yes}$ $\square_{No}$ ical Information:	Date: / /	Hep B ruled out/treated	: □ <sub>Yes</sub> I	No Date:	1 1	_		
INJECTION TRAINING									
□ Patient has received pen and injection training □ Physician's office to provide injection training □ Senderra to coordinate injection training  PRESCRIBER SIGNATURE									
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra Rx to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay									
assistance foundations.  Prescriber:  Date:									
			OMERCHIAL ITY						
	IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.								

Juvenile Idiopathic Arthritis Enrollment (Rev. 3/28/2025)